Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634271 | 0.86 | JAK3 (0.42) | HTR6TRPV1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL17634298 | 0.83 | CKS1B (0.45) | LMNAMAPT | |
| SCHEMBL28587642 | 0.81 | POLB (0.44) | HTR6PIK3CDPIK3CAPIK3CBLMNA | |
| SCHEMBL26683753 | 0.78 | DRD2 (0.47) | HTR6LMNAMAPTDRD2DRD4 | |
| SCHEMBL19284723 | 0.75 | HTR6 (0.65) | HTR6LMNAMAPTDRD2DRD4 | |
| SCHEMBL31073939 | 0.74 | TDO2 (0.54) | TRPV1 | |
| SCHEMBL27804607 | 0.73 | TRPV1 (0.58) | TRPV1MAPT | |
| SCHEMBL25275764 | 0.72 | TRPC5 (0.60) | TRPC5 | |
| SCHEMBL25237273 | 0.70 | TRPC5 (0.39) | TRPV1TRPC5LMNA | |
| SCHEMBL30125124 | 0.69 | NOS1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| EP-3197870-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049524-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | HTR6 4832/4885TRPV1 4520/4885PIK3CD 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.